Key result
Statin use is not linked to lower chemotherapy-induced peripheral neuropathy risk in cancer patients.
Why the study?
Given statins have neuroprotective properties and are widely used, their safety and efficacy on chemotherapy-induced peripheral neuropathy remained to be investigated.
Does statin use prevent chemotherapy-induced peripheral neuropathy and improve overall survival in patients receiving oxaliplatin, paclitaxel, or nab-paclitaxel?
Observational (n=3,822)
Does statin use prevent chemotherapy-induced peripheral neuropathy and improve overall survival in patients receiving oxaliplatin, paclitaxel, or nab-paclitaxel?
Statin use in cancer patients receiving cytotoxic chemotherapy does not reduce the overall incidence of chemotherapy-induced peripheral neuropathy, though it may be associated with improved overall survival specifically in men receiving paclitaxel.
Answers are grounded in this paper and cite their sources.
Statin use was not associated with lower CIPN incidence; leaves open neuroprotective effects in other settings.
BACKGROUND: Statins, hydroxymethylglutaryl-CoA reductase inhibitors, possess neuroprotective properties. Given the potential neuroprotective properties of statins and their prevalent use in clinical settings, we aimed to investigate their impact on chemotherapy-induced peripheral neuropathy (CIPN) in Japan by assessing both their safety and efficacy in this context. METHODS: We conducted a retrospective observational study using the Japan Medical Data Centre database, which includes data from 2005 to 2021. We included patients who underwent anticancer therapy and were categorized into non-statin (10,920) and statin (1,537) groups. These groups were matched using a propensity score, resulting in 2,548 non-statin and 1,274 statin users. The primary endpoints were the incidence of CIPN post-first prescription of each anticancer drug and overall survival. RESULTS: Treatment with statins did not increase the incidence of CIPN (non-statin 27.2% vs. statin 28.4%, P = 0.443). Nevertheless, the incidence of CIPN was significantly high among women (non-statin 28.0% vs. statin 33.2%, P = 0.025). Overall survival was not impacted by statin use (hazard ratio 0.98, 95%CI: 0.83-1.16, P = 0.8846). Among men treated with paclitaxel, we observed an improvement in overall survival (hazard ratio: 0.72; 95% CI: 0.56-0.92; P = 0.0110). CONCLUSIONS: The use of statins in patients with cancer was not associated with CIPN incidence. However, in men receiving paclitaxel treatment, statins may be linked to improved overall survival. Further studies are necessary to clarify the factors influencing prognosis and CIPN severity.
No takes yet. Share an insight, caveat, or question.
Aizawa et al. (2025) conducted an observational in Cancer (treated with oxaliplatin, paclitaxel, or nab-paclitaxel) (n=3,822). Statins vs. Non-statin users was evaluated on Incidence of chemotherapy-induced peripheral neuropathy (CIPN) (HR 1.05, 95% CI 0.92-1.19, p=0.4230). Statin use in patients with cancer receiving oxaliplatin, paclitaxel, or nab-paclitaxel did not affect the cumulative incidence of chemotherapy-induced peripheral neuropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: